EXACT Sciences Corporation (NASDAQ: EXAS)

EXACT Sciences Corporation (NASDAQ: EXAS) is focused on developing technologies that help to eliminate mortality from common cancers through the leveraging of advances in the field of genomics to facilitate the early detection of disease. The company’s first target is colorectal cancer, which is the second leading cause of cancer deaths as well as the most deadly cancer among non-smoking men and women in the U.S., providing the company with a large opportunity. For further information, visit the Company’s web site at www.exactsciences.com.